Two mouse models of Alzheimer's disease accumulate amyloid at different rates and have distinct Aβ oligomer profiles unaltered by ablation of cellular prion protein.

Oligomers formed from monomers of the amyloid β-protein (Aβ) are thought to be central to the pathogenesis of Alzheimer's disease (AD). Unsurprisingly for a complex disease, current mouse models of AD fail to fully mimic the clinical disease in humans. Moreover, results obtained in a given mous...

Full description

Bibliographic Details
Main Authors: Silvia A Purro, Michael Farmer, Elizabeth Noble, Claire J Sarell, Megan Powell, Daniel Yip, Lauren Giggins, Leila Zakka, David X Thomas, Mark Farrow, Andrew J Nicoll, Dominic Walsh, John Collinge
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0294465
_version_ 1797394626659745792
author Silvia A Purro
Michael Farmer
Elizabeth Noble
Claire J Sarell
Megan Powell
Daniel Yip
Lauren Giggins
Leila Zakka
David X Thomas
Mark Farrow
Andrew J Nicoll
Dominic Walsh
John Collinge
author_facet Silvia A Purro
Michael Farmer
Elizabeth Noble
Claire J Sarell
Megan Powell
Daniel Yip
Lauren Giggins
Leila Zakka
David X Thomas
Mark Farrow
Andrew J Nicoll
Dominic Walsh
John Collinge
author_sort Silvia A Purro
collection DOAJ
description Oligomers formed from monomers of the amyloid β-protein (Aβ) are thought to be central to the pathogenesis of Alzheimer's disease (AD). Unsurprisingly for a complex disease, current mouse models of AD fail to fully mimic the clinical disease in humans. Moreover, results obtained in a given mouse model are not always reproduced in a different model. Cellular prion protein (PrPC) is now an established receptor for Aβ oligomers. However, studies of the Aβ-PrPC interaction in different mouse models have yielded contradictory results. Here we performed a longitudinal study assessing a range of biochemical and histological features in the commonly used J20 and APP-PS1 mouse models. Our analysis demonstrated that PrPC ablation had no effect on amyloid accumulation or oligomer production. However, we found that APP-PS1 mice had higher levels of oligomers, that these could bind to recombinant PrPC, and were recognised by the OC antibody which distinguishes parallel, in register fibrils. On the other hand, J20 mice had a lower level of Aβ oligomers, which did not interact with PrPC when tested in vitro and were OC-negative. These results suggest the two mouse models produce diverse Aβ assemblies that could interact with different targets, highlighting the necessity to characterise the conformation of the Aβ oligomers concomitantly with the toxic cascade elicited by them. Our results provide an explanation for the apparent contradictory results found in APP-PS1 mice and the J20 mouse line in regards to Aβ toxicity mediated by PrPC.
first_indexed 2024-03-09T00:22:30Z
format Article
id doaj.art-8af80f9aedd94ca28f2439779fee4821
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-03-09T00:22:30Z
publishDate 2023-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-8af80f9aedd94ca28f2439779fee48212023-12-12T05:33:51ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-011811e029446510.1371/journal.pone.0294465Two mouse models of Alzheimer's disease accumulate amyloid at different rates and have distinct Aβ oligomer profiles unaltered by ablation of cellular prion protein.Silvia A PurroMichael FarmerElizabeth NobleClaire J SarellMegan PowellDaniel YipLauren GigginsLeila ZakkaDavid X ThomasMark FarrowAndrew J NicollDominic WalshJohn CollingeOligomers formed from monomers of the amyloid β-protein (Aβ) are thought to be central to the pathogenesis of Alzheimer's disease (AD). Unsurprisingly for a complex disease, current mouse models of AD fail to fully mimic the clinical disease in humans. Moreover, results obtained in a given mouse model are not always reproduced in a different model. Cellular prion protein (PrPC) is now an established receptor for Aβ oligomers. However, studies of the Aβ-PrPC interaction in different mouse models have yielded contradictory results. Here we performed a longitudinal study assessing a range of biochemical and histological features in the commonly used J20 and APP-PS1 mouse models. Our analysis demonstrated that PrPC ablation had no effect on amyloid accumulation or oligomer production. However, we found that APP-PS1 mice had higher levels of oligomers, that these could bind to recombinant PrPC, and were recognised by the OC antibody which distinguishes parallel, in register fibrils. On the other hand, J20 mice had a lower level of Aβ oligomers, which did not interact with PrPC when tested in vitro and were OC-negative. These results suggest the two mouse models produce diverse Aβ assemblies that could interact with different targets, highlighting the necessity to characterise the conformation of the Aβ oligomers concomitantly with the toxic cascade elicited by them. Our results provide an explanation for the apparent contradictory results found in APP-PS1 mice and the J20 mouse line in regards to Aβ toxicity mediated by PrPC.https://doi.org/10.1371/journal.pone.0294465
spellingShingle Silvia A Purro
Michael Farmer
Elizabeth Noble
Claire J Sarell
Megan Powell
Daniel Yip
Lauren Giggins
Leila Zakka
David X Thomas
Mark Farrow
Andrew J Nicoll
Dominic Walsh
John Collinge
Two mouse models of Alzheimer's disease accumulate amyloid at different rates and have distinct Aβ oligomer profiles unaltered by ablation of cellular prion protein.
PLoS ONE
title Two mouse models of Alzheimer's disease accumulate amyloid at different rates and have distinct Aβ oligomer profiles unaltered by ablation of cellular prion protein.
title_full Two mouse models of Alzheimer's disease accumulate amyloid at different rates and have distinct Aβ oligomer profiles unaltered by ablation of cellular prion protein.
title_fullStr Two mouse models of Alzheimer's disease accumulate amyloid at different rates and have distinct Aβ oligomer profiles unaltered by ablation of cellular prion protein.
title_full_unstemmed Two mouse models of Alzheimer's disease accumulate amyloid at different rates and have distinct Aβ oligomer profiles unaltered by ablation of cellular prion protein.
title_short Two mouse models of Alzheimer's disease accumulate amyloid at different rates and have distinct Aβ oligomer profiles unaltered by ablation of cellular prion protein.
title_sort two mouse models of alzheimer s disease accumulate amyloid at different rates and have distinct aβ oligomer profiles unaltered by ablation of cellular prion protein
url https://doi.org/10.1371/journal.pone.0294465
work_keys_str_mv AT silviaapurro twomousemodelsofalzheimersdiseaseaccumulateamyloidatdifferentratesandhavedistinctaboligomerprofilesunalteredbyablationofcellularprionprotein
AT michaelfarmer twomousemodelsofalzheimersdiseaseaccumulateamyloidatdifferentratesandhavedistinctaboligomerprofilesunalteredbyablationofcellularprionprotein
AT elizabethnoble twomousemodelsofalzheimersdiseaseaccumulateamyloidatdifferentratesandhavedistinctaboligomerprofilesunalteredbyablationofcellularprionprotein
AT clairejsarell twomousemodelsofalzheimersdiseaseaccumulateamyloidatdifferentratesandhavedistinctaboligomerprofilesunalteredbyablationofcellularprionprotein
AT meganpowell twomousemodelsofalzheimersdiseaseaccumulateamyloidatdifferentratesandhavedistinctaboligomerprofilesunalteredbyablationofcellularprionprotein
AT danielyip twomousemodelsofalzheimersdiseaseaccumulateamyloidatdifferentratesandhavedistinctaboligomerprofilesunalteredbyablationofcellularprionprotein
AT laurengiggins twomousemodelsofalzheimersdiseaseaccumulateamyloidatdifferentratesandhavedistinctaboligomerprofilesunalteredbyablationofcellularprionprotein
AT leilazakka twomousemodelsofalzheimersdiseaseaccumulateamyloidatdifferentratesandhavedistinctaboligomerprofilesunalteredbyablationofcellularprionprotein
AT davidxthomas twomousemodelsofalzheimersdiseaseaccumulateamyloidatdifferentratesandhavedistinctaboligomerprofilesunalteredbyablationofcellularprionprotein
AT markfarrow twomousemodelsofalzheimersdiseaseaccumulateamyloidatdifferentratesandhavedistinctaboligomerprofilesunalteredbyablationofcellularprionprotein
AT andrewjnicoll twomousemodelsofalzheimersdiseaseaccumulateamyloidatdifferentratesandhavedistinctaboligomerprofilesunalteredbyablationofcellularprionprotein
AT dominicwalsh twomousemodelsofalzheimersdiseaseaccumulateamyloidatdifferentratesandhavedistinctaboligomerprofilesunalteredbyablationofcellularprionprotein
AT johncollinge twomousemodelsofalzheimersdiseaseaccumulateamyloidatdifferentratesandhavedistinctaboligomerprofilesunalteredbyablationofcellularprionprotein